Skip to content

Released Aug 7, 2025, after the close

10-Q filed Aug 7, 2025, 38 days after period end · 0000950170-25-105219

Q2 2025 · 10-Q
Revenue$63.75M+148.0% vs Q2 2024+266.4% vs Q1 2025
Net Income-$11.50MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$1.35N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$3,345,000N/M
Operating Cash Flowderived-$44,724,000N/M
Margins · derived
Operating margin-5.2%+184.1 pt vs Q2 2024
Net margin-18.0%+168.8 pt vs Q2 2024

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$63.75M$25.71M$10.41M$28.10M
Net Income-$11.50M-$48.02M-$38.52M-$26.01M
EPS Diluted-$1.35-$0.59-$0.64-$0.55

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR